GJB5 association with BRAF mutation and survival in cutaneous malignant melanoma

Abstract

Funding sourcesA.P. was funded by the British Skin Foundation (grant number 6063s to D.B.); M.M.-G. and P.O. were funded by Fondazione CRT (grant number ID.73150) to G.C.

Melanoma metastasis, BRAF mutation and GJB5 connexin expression: a new prognostic factor

“…The authors further address the compound N-acetyl-GED-0507-34-Levo (NAGED), a peroxisome proliferator-activated receptor-c agonist known to inhibit the EMT of eHFSCs. 5,6 In the present model, preadministration of NAGED counteracts repeated 4-HC treatment and inhibits not only EMT, but also the apoptosis of eHFSCs. 2 These results indicate that NAGED is a promising molecule that could be used for the prevention of pCIA.…”

“…This points to a novel mechanism of BRAF V600E‐mediated control of gap junctions through an axis involving miR‐335. In tissues, miR‐335 and BRAF V600E co‐occur in melanoma 5 . Consistently with the tumour‐suppressive role attributed to connexins, 7 increased expression of GJB5 correlates with better overall survival 5 .…”

“…In tissues, miR-335 and BRAF V600E co-occur in melanoma. 5 Consistently with the tumour-suppressive role attributed to connexins, 7 increased expression of GJB5 correlates with better overall survival. 5 The study's importance resides in identifying a new prognostic factor for metastatic melanoma and showing a novel mechanism of gap-junction modulation in BRAF-mutated malignant melanoma following a BRAF V600E-miR-335-GJB5 axis.…”

“…Using these datasets and an independent cohort of isolated melanomas, in the current issue of the BJD , Scatolini et al 5 . established an association of reduced expression of connexin 31·1 (GJB5), a gap‐junction protein, with metastatic melanoma and BRAF mutational status 5 .…”

“…Using these datasets and an independent cohort of isolated melanomas, in the current issue of the BJD, Scatolini et al 5 established an association of reduced expression of connexin 31Á1 (GJB5), a gap-junction protein, with metastatic melanoma and BRAF mutational status. 5 Reduced expression of GJB5 was previously identified in a small cohort of patients by expression profiling of melanoma metastases compared with primary lesions. 6 Still, the role of GJB5 in melanoma is not known.…”